ReviewFrontiers in cardiovascular medicine2021
Antidepressant Drugs Effects on Blood Pressure.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- Repetitive transcranial magnetic stimulation for late-life depression: A systematic review and meta-analysis of randomized controlled trials.The Journal of international medical research · 2025Pooled it
- Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.Inflammatory bowel diseases · 2025Trial
- Severe orthostatic hypotension after left atrial appendage occlusion.HeartRhythm case reports · 2026Article
- Reflex vasodilation and sweating in response to passive whole body heating are blunted in women with major depressive disorder.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Comparative Pharmacological Profiling of Psychotherapeutic Drugs Reveals a Functional Taxonomy Based on Direct Inhibition of Smooth Muscle Excitability.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome.Communications medicine · 2026Article
- Optimizing antidepressant use in geriatric depression: expert consensus from French societies of geriatrics, old age psychiatry, and clinical pharmacy (SFGG, SF3PA, and SFPC).European psychiatry : the journal of the Association of European Psychiatrists · 2026Article
- Involvement of Serotonergic and Dopaminergic Systems inPharmaceuticals (Basel, Switzerland) · 2026Article
- Drug-associated hypertensive crisis: a disproportionality analysis of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Combined Effects of Depression, Fatigue and Cardiovascular Dysfunction on Functional Dependence Over Seven Years in Early Parkinson's Disease.Movement disorders clinical practice · 2026Article
- A survey on the clinical practice of herpes zoster and postherpetic neuralgia management by Korean medicine doctors: towards the development of Korean medicine clinical practice guidelines.BMC complementary medicine and therapies · 2026Article
- The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database.Frontiers in pharmacology · 2026Article
- A unifying theory of brain signaling and its possible role in acquired chronic disease.Frontiers in neuroscience · 2026Article
- Treating hearts and minds: adverse cardiovascular effects of psychiatric medications.Therapeutic advances in drug safety · 2026Review
- A review of risk factors and intervention measures for comorbidity of diabetes and mental disorders.Frontiers in psychiatry · 2026Review
- The influence of fluoxetine on the blood pressure: a meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2026Review
- Efficacy and Safety of Desvenlafaxine for the Treatment of Persistent Idiopathic Dentoalveolar Pain: A Retrospective Observational Study.Pain research & management · 2026Observational
- The Overlooked Driver of Hypertension: Mental Stress at the Crossroad of Cardiology and Psychiatry.Current atherosclerosis reports · 2025Review
- The efficacy and safety of antidepressants as alternative treatment of attention-deficit/hyperactivity disorder in pediatric populations.The mental health clinician · 2025Review
- The impact of sertraline treatment on obesity, inflammation, blood pressure, and lipid profiles: a systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2025Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals suffering from depressive disorders display a greater incidence of hypertension compared with the general population, despite reports of the association between depression and hypotension. This phenomenon may depend, at least in part, on the use of antidepressant drugs, which may influence blood pressure through different effects on adrenergic and serotoninergic pathways, as well as on histaminergic, dopaminergic, and cholinergic systems. This review summarizes extant literature on the effect of antidepressant drugs on blood pressure. Selective serotonin reuptake inhibitors are characterized by limited effects on autonomic system activity and a lower impact on blood pressure. Thus, they represent the safest class-particularly among elderly and cardiovascular patients. Serotonin-norepinephrine reuptake inhibitors, particularly venlafaxine, carry a greater risk of hypertension, possibly related to greater effects on the sympathetic nervous system. The norepinephrine reuptake inhibitor reboxetine is considered a safe option because of its neutral effects on blood pressure in long-term studies, even if both hypotensive and hypertensive effects are reported. The dopamine-norepinephrine reuptake inhibitor bupropion can lead to blood pressure increases, usually at high doses, but may also cause orthostatic hypotension, especially in patients with cardiovascular diseases. The norepinephrine-serotonin modulators, mirtazapine and mianserin, have minimal effects on blood pressure but may rarely lead to orthostatic hypotension and falls. These adverse effects are also observed with the serotonin-reuptake modulators, nefazodone and trazodone, but seldomly with vortioxetine and vilazodone. Agomelatine, the only melatonergic antidepressant drug, may also have limited effects on blood pressure. Tricyclic antidepressants have been associated with increases in blood pressure, as well as orthostatic hypotension, particularly imipramine. Oral monoamine-oxidase inhibitors, less frequently skin patch formulations, have been associated with orthostatic hypotension or, conversely, with hypertensive crisis due to ingestion of tyramine-containing food (i.e., cheese reaction). Lastly, a hypertensive crisis may complicate antidepressant treatment as a part of the serotonin syndrome, also including neuromuscular, cognitive, and autonomic dysfunctions. Clinicians treating depressive patients should carefully consider their blood pressure status and cardiovascular comorbidities because of the effects of antidepressant drugs on blood pressure profiles and potential interactions with antihypertensive treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.